Literature DB >> 29914979

Dynamic intercellular redistribution of HIT antigen modulates heparin-induced thrombocytopenia.

Jing Dai1,2, Daria Madeeva1, Vincent Hayes1,3, Hyun Sook Ahn1, Valerie Tutwiler1,4, Gowthami M Arepally5, Douglas B Cines3, Mortimer Poncz1,6, Lubica Rauova1,6.   

Abstract

Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder initiated by antibodies to platelet factor 4 (PF4)/heparin complexes. PF4 released from platelets binds to surface glycosaminoglycans on hematopoietic and vascular cells that are heterogenous in composition and differ in affinity for PF4. PF4 binds to monocytes with higher affinity than to platelets, and depletion of monocytes exacerbates thrombocytopenia in a murine HIT model. Here we show that the expression of PF4 on platelets and development of thrombocytopenia are modulated by the (re)distribution of PF4 among hematopoietic and endothelial cell surfaces. Binding of PF4 to platelets in whole blood in vitro varies inversely with the white cell count, likely because of the greater affinity of monocytes for PF4. In mice, monocyte depletion increased binding of PF4 to platelets by two- to three-fold. Induction of HIT in mice caused a transient >80-fold increase in binding of HIT antibody to monocytes vs 3.5-fold increase to platelets and rapid transient monocytopenia. Normalization of monocyte counts preceded the return in platelet counts. Exposure of blood to endothelial cells also depletes PF4 from platelet surfaces. These studies demonstrate a dynamic interchange of surface-bound PF4 among hematopoetic and vascular cells that may limit thrombocytopenia at the expense of promoting prothrombotic processes in HIT.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29914979      PMCID: PMC6097133          DOI: 10.1182/blood-2018-02-830737

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  42 in total

1.  Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.

Authors:  J Amiral; F Bridey; M Dreyfus; A M Vissoc; E Fressinaud; M Wolf; D Meyer
Journal:  Thromb Haemost       Date:  1992-07-06       Impact factor: 5.249

2.  A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis.

Authors:  Anand Padmanabhan; Curtis G Jones; Brian R Curtis; Daniel W Bougie; Mia J Sullivan; Namrata Peswani; Janice G McFarland; Daniel Eastwood; Demin Wang; Richard H Aster
Journal:  Chest       Date:  2016-02-19       Impact factor: 9.410

3.  IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia.

Authors:  Anand Padmanabhan; Curtis G Jones; Shannon M Pechauer; Brian R Curtis; Daniel W Bougie; Mehraboon S Irani; Barbara J Bryant; Jack B Alperin; Thomas G Deloughery; Kevin P Mulvey; Binod Dhakal; Renren Wen; Demin Wang; Richard H Aster
Journal:  Chest       Date:  2017-04-17       Impact factor: 9.410

4.  Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies.

Authors:  G M Arepally; S Kamei; K S Park; K Kamei; Z Q Li; W Liu; D L Siegel; W Kisiel; D B Cines; M Poncz
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

5.  Proteoglycans synthesized in vitro by nude and normal mouse peritoneal macrophages.

Authors:  V L Petricevich; Y M Michelacci
Journal:  Biochim Biophys Acta       Date:  1990-07-12

6.  Polymorphonuclear leukocyte and monocyte activation induced by plasma from patients with heparin-induced thrombocytopenia in whole blood.

Authors:  Mahnouch Khairy; Dominique Lasne; Aymeric Amelot; Malvina Crespin; Francine Rendu; Martine Aiach; Christilla Bachelot-Loza
Journal:  Thromb Haemost       Date:  2004-12       Impact factor: 5.249

7.  Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia.

Authors:  C Pouplard; S Iochmann; B Renard; O Herault; P Colombat; J Amiral; Y Gruel
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

8.  Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion.

Authors:  Zhihua Xiao; Gian P Visentin; Kannayakanahalli M Dayananda; Sriram Neelamegham
Journal:  Blood       Date:  2008-06-06       Impact factor: 22.113

9.  Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.

Authors:  G P Visentin; S E Ford; J P Scott; R H Aster
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

10.  Atomic description of the immune complex involved in heparin-induced thrombocytopenia.

Authors:  Zheng Cai; Serge V Yarovoi; Zhiqiang Zhu; Lubica Rauova; Vincent Hayes; Tatiana Lebedeva; Qun Liu; Mortimer Poncz; Gowthami Arepally; Douglas B Cines; Mark I Greene
Journal:  Nat Commun       Date:  2015-09-22       Impact factor: 14.919

View more
  3 in total

Review 1.  Clinical impact of glycans in platelet and megakaryocyte biology.

Authors:  Hervé Falet; Leonardo Rivadeneyra; Karin M Hoffmeister
Journal:  Blood       Date:  2022-06-02       Impact factor: 25.476

2.  Near fatal stent thrombosis in an aneurysmatic RCX as first manifestation of heparin induced thrombocytopenia (HIT) without thrombocytopenia.

Authors:  Marc Zoller; Iskandar Atmowihardjo; Jeanette Huch; Ines Albrecht; Dirk Habedank
Journal:  BMC Cardiovasc Disord       Date:  2021-12-31       Impact factor: 2.298

3.  FcRn augments induction of tissue factor activity by IgG-containing immune complexes.

Authors:  Douglas B Cines; Sergei Zaitsev; Lubica Rauova; Ann H Rux; Victoria Stepanova; Sriram Krishnaswamy; Amrita Sarkar; M Anna Kowalska; Guohua Zhao; Alan E Mast; Laurence J Blumberg; Keith R McCrae; Mortimer Poncz; Jonathan J Hubbard; Michal Pyzik; Richard S Blumberg
Journal:  Blood       Date:  2020-06-04       Impact factor: 22.113

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.